Charlotte, N.C.-based Dentsply Sirona reported $898 million in net sales for the second quarter of 2026, a 4.1% decline from $936 million in the same period last year, according to an Aug. 6 earnings release.
Net income attributable to Dentsply Sirona was $37 million, compared to a net loss of $45 million in Q2 2025. Adjusted EBITDA was $190 million, down slightly from $197 million in Q2 2025.
The steepest decline in net sales came from the company’s Orthodontic and Implant Solutions segment, which fell 13.2% to $197 million. Essential Dental Solutions declined 2.7% to $376 million, while Connected Technology Solutions fell 1.5% to $239 million. Wellspect Healthcare rose 7.1% to $86 million.
Operating cash flow improved from $48 million in Q2 2025 to $99 million in Q2 2026, aided by approximately $44 million in tariff refunds. The company also repurchased 1.3 million shares for $12 million during the quarter, and held $239 million in cash as of June 30.
Dentsply Sirona maintained its full-year 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
President and CEO Dan Scavilla said the company is making “meaningful progress” in several high priority areas as it executes its Return-to-Growth Action plan. The action plan was launched in November to position the company for sustainable growth over the next 24 months.
